Amgen completed the acquisition of ChemoCentryx for $3.7bn.

Amgen, a biotechnology company, completed the acquisition of ChemoCentryx, a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, for $3.7bn. "The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with TAVNEOS, a transformative, first-in-class treatment for ANCA-associated vasculitis. We are excited to join in the TAVNEOS launch and help many more patients with this serious and sometimes life-threatening disease for which there remains significant unmet medical need. We also look forward to welcoming the highly skilled team from ChemoCentryx that shares our passion for serving patients suffering from serious diseases," Robert A. Bradway, Amgen Chairman and CEO.